<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00491868</url>
  </required_header>
  <id_info>
    <org_study_id>JH20876</org_study_id>
    <nct_id>NCT00491868</nct_id>
  </id_info>
  <brief_title>Clinical Study of R744 to Hemodialysis Patients</brief_title>
  <official_title>Switch and Maintenance Study of Intravenous Injections of R744 to Hemodialysis Patients ( Phase III, Double Blind Study in Comparison With Epoetin Beta).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chugai Pharmaceutical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study used as the comparative drug (epoetin beta) will assess the efficacy and safety of
      intravenous injections of R744 in renal anemia patients on Hemodialysis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation of Hb concentration from baseline Hb concentration in evaluation period</measure>
    <time_frame>week 17~24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients who maintain Hb concentration in the range of baseline ± 1.0g/dL and maintain Hb concentration in the range of ≥ 9.0g/dL and ≤ 12.0g/dL in evaluation period</measure>
    <time_frame>week 17~24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients who maintain Hb concentration within ±1.0g/dL of reference Hb</measure>
    <time_frame>week 17~24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory measurements</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs, standard 12-lead ECG</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-R744 antibody titer</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-Epoetin beta antibody titer</measure>
    <time_frame>throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Hemodialysis Patients</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R744</intervention_name>
    <description>100μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>methoxy polyethylene glycol-epoetin beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R744</intervention_name>
    <description>150μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>methoxy polyethylene glycol-epoetin beta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHuEPO</intervention_name>
    <description>2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHuEPO</intervention_name>
    <description>4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R744 placebo</intervention_name>
    <description>0 μg/4week for 24 weeks</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rHuEPO placebo</intervention_name>
    <description>0 IU 2 or 3 times/week for 8 weeks, then 1~3 times/week for 16 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have been receiving hemodialysis 3 times a week for at least 12 weeks
             before registration

          -  Patients aged ≥ 20 years at the time of obtaining consent

          -  Patients who have been receiving a rHuEPO preparation at least once a week for at
             least 8 weeks before registration

          -  Within 4 weeks before registration, patients who have been receiving a rHuEPO
             preparation 750IU (3 times a week), 1,500IU (twice a week (1st and 2nd hemodialysis
             day of the week, or1st and 3rd hemodialysis day of the week)), 1,500IU (3 times a
             week), or 3,000IU (twice a week (1st and 2nd hemodialysis day of the week, or1st and
             3rd hemodialysis day of the week)), and patients who have not change dosage and
             administration.

          -  Patients whose pre-dialysis Hb concentrations has been between ≥ 9.0 g/dL and ≤12.0
             g/dL and mean value of pre-dialysis Hb concentrations has been between ≥ 9.5 g/dL and
             ≤11.5 g/dL determined at the beginning of each week within 8 weeks before registration

          -  Patients whose transferrin saturation has been ≥ 20 % or ferritin has been ≥ 100ng/mL
             at any time point within 8 weeks before registration

        Exclusion Criteria:

          -  Patients with hardly controllable hypertension (patients whose diastolic blood
             pressure has been ≥ 100 mmHg on more than 1/3 of the determining occasions within 12
             weeks before registration)

          -  Patients with congestive cardiac failure (≥ Class III in NYHA cardiac function
             classification)

          -  Female patients who are pregnant, lactating, possibly pregnant or not willing to take
             a contraceptive measure in the period from the day of starting the treatment with the
             study drug to 90 days after the day of the last dose of the study drug

          -  Patients with complication of myocardial infarction, pulmonary infarction or cerebral
             infarction (excluding asymptomatic cerebral infarction)

          -  Patients confirmed to have serious allergy or serious drug allergy (shock,
             anaphylactoid symptom)

          -  Patients hypersensitive to a rHuEPO preparation

          -  Patients with malignant tumor (including hemic malignant tumor), severe infection,
             systemic hemic disease (osteomyelodysplasia syndrome, hemoglobinopathy, etc.),
             hemolytic anemia or apparent hemorrhagic lesion such as digestive tract hemorrhage

          -  Patients who have received an anabolic hormone preparation, testosterone enanthate,
             testosterone propionate, methyltestosterone or mepitiostane within 12 weeks before
             registration

          -  Patients who have received another investigational drug within 12 weeks before
             registration

          -  Patients who have received R744 before registration

          -  Patients whose AST(GOT) value ≥ 100 IU/L or ALT(GPT) value ≥ 100 IU/L before
             registration

          -  Patients who have received erythrocyte transfusion within 16 weeks before registration

          -  Patients for whom a surgical operation accompanied by marked bleeding is planned
             during the study period

          -  In addition, patients who are judged as ineligible to participate in this study by the
             investigator or subinvestigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takanori Baba</last_name>
    <role>Study Chair</role>
    <affiliation>Chugai Pharmaceutical,Clinical Research Department 2</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chubu region</name>
      <address>
        <city>Chubu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chugoku/Shikoku region</name>
      <address>
        <city>Chugoku/Shikoku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto/Koshinetsu region</name>
      <address>
        <city>Kanto/Koshinetsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki/Hokuriku region</name>
      <address>
        <city>Kinki/Hokuriku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyusyu region</name>
      <address>
        <city>Kyusyu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2007</study_first_submitted>
  <study_first_submitted_qc>June 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2007</study_first_posted>
  <last_update_submitted>January 29, 2009</last_update_submitted>
  <last_update_submitted_qc>January 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Chugai Pharmaceutical</name_title>
    <organization>Chugai Pharmaceutical</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

